{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disorder&page=38",
    "query": {
      "condition": "Retinal Disorder",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 1622,
    "total_pages": 163,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disorder&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disorder&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T19:40:00.713Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01272076",
      "title": "Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age Related Macular Degeneration",
        "Geographic Atrophy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Carl Zeiss Meditec, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2011-01",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2014-01-20",
      "last_synced_at": "2026-11-07T19:40:00.713Z",
      "location_count": 2,
      "location_summary": "Oakland, California • Jackson, Michigan",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Jackson",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01272076"
    },
    {
      "nct_id": "NCT02043470",
      "title": "Retinal Oxygen Function After Radiation Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "A History of Radiation Therapy for a Tumor in the Vicinity of the Retina(s)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 32,
      "start_date": "2011-03",
      "completion_date": "2017-05-04",
      "has_results": false,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-11-07T19:40:00.713Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02043470"
    },
    {
      "nct_id": "NCT03922932",
      "title": "WF and PR OCTA in Diabetic Retinopathy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 290,
      "start_date": "2017-08-30",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-11-07T19:40:00.713Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03922932"
    },
    {
      "nct_id": "NCT00403039",
      "title": "Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Ranibizumab (Lucentis )",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vitreous -Retina- Macula Consultants of New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 41,
      "start_date": "2006-11",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2016-01-01",
      "last_synced_at": "2026-11-07T19:40:00.713Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00403039"
    },
    {
      "nct_id": "NCT00042211",
      "title": "Preventing Depression in Patients With Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depression",
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Problem Solving Treatment",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2001-02",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2014-01-08",
      "last_synced_at": "2026-11-07T19:40:00.713Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042211"
    },
    {
      "nct_id": "NCT03917472",
      "title": "Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Brolucizumab",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 517,
      "start_date": "2019-07-17",
      "completion_date": "2021-03-24",
      "has_results": true,
      "last_update_posted_date": "2022-08-12",
      "last_synced_at": "2026-11-07T19:40:00.713Z",
      "location_count": 74,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 66 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03917472"
    },
    {
      "nct_id": "NCT02403128",
      "title": "Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery Macroaneurysms",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Macular Edema",
        "Retinal Artery Macroaneurysm"
      ],
      "interventions": [
        {
          "name": "aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kamal Kishore, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2015-05-14",
      "completion_date": "2020-02",
      "has_results": false,
      "last_update_posted_date": "2019-08-08",
      "last_synced_at": "2026-11-07T19:40:00.713Z",
      "location_count": 1,
      "location_summary": "Peoria, Illinois",
      "locations": [
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02403128"
    },
    {
      "nct_id": "NCT00685399",
      "title": "Safety and Efficacy of AIN457 in Noninfectious Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-infectious Uveitis"
      ],
      "interventions": [
        {
          "name": "AIN457",
          "type": "DRUG"
        },
        {
          "name": "AIN 457",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 76,
      "start_date": "2008-06",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2017-07-17",
      "last_synced_at": "2026-11-07T19:40:00.713Z",
      "location_count": 20,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00685399"
    },
    {
      "nct_id": "NCT00211484",
      "title": "Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degenerations.",
        "Subfoveal Neovascularization."
      ],
      "interventions": [
        {
          "name": "Anecortave Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Manhattan Eye, Ear & Throat Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2003-05",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2007-05-07",
      "last_synced_at": "2026-11-07T19:40:00.713Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00211484"
    },
    {
      "nct_id": "NCT06333249",
      "title": "A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "X-Linked Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "rAAV2tYF-GRK1-RPGR",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Beacon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "8 Years to 50 Years · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2021-04-13",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2024-08-12",
      "last_synced_at": "2026-11-07T19:40:00.713Z",
      "location_count": 6,
      "location_summary": "Jacksonville, Florida • Boston, Massachusetts • Cincinnati, Ohio + 3 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06333249"
    }
  ]
}